January 14, 2021 07:04 AM ESTUpdated 10:27 AM
Coronavirus

Covid-19 roundup: Alex­ion's C5 in­hibitor Ul­tomiris miss­es the PhI­II bar; Lon­za in wait­ing game to use in­gre­di­ents in Mod­er­na vac­cine

Amber Tong

Conner Mitchell

C5 in­hi­bi­tion isn’t the an­swer to the search for treat­ments for se­vere Covid-19 af­ter all.

Alex­ion is paus­ing en­roll­ment to a Phase III study test­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Boehringer’s up­dat­ed re­sults in HER2-mu­tat­ed lung can­cer im­press

No­vavax re­sponds to FDA’s tri­al ask, with Covid vac­cine strain up­dates un­der scruti­ny

Mer­ck KGaA to buy rare can­cer biotech Spring­Works for $3.9B

Schol­ar Rock names new CEO, adds biotech vet­er­ans in C-suite re­build

GSK’s check­point block­er Jem­per­li cures bio­mark­er-dri­ven rec­tal can­cer

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times